Armenia

Armenia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.09 (1.72 - 2.37) 2019 Modelled IHME
2.12 (1.79 - 2.40) 2018 Modelled IHME
2.14 (1.78 - 2.46) 2017 Modelled IHME
2.14 (1.80 - 2.45) 2016 Modelled IHME
2.15 (1.76 - 2.47) 2015 Modelled IHME
2.18 (1.79 - 2.49) 2014 Modelled IHME
2.23 (1.87 - 2.57) 2013 Modelled IHME
2.3 (1.94 - 2.66) 2012 Modelled IHME
2.37 (2.01 - 2.76) 2011 Modelled IHME
2.44 (2.06 - 2.87) 2010 Modelled IHME
2.49 (2.11 - 2.91) 2009 Modelled IHME
2.55 (2.14 - 2.95) 2008 Modelled IHME
2.6 (2.17 - 3.03) 2007 Modelled IHME
2.65 (2.20 - 3.11) 2006 Modelled IHME
2.7 (2.22 - 3.18) 2005 Modelled IHME
2.75 (2.27 - 3.21) 2004 Modelled IHME
2.8 (2.33 - 3.26) 2003 Modelled IHME
2.85 (2.37 - 3.30) 2002 Modelled IHME
2.89 (2.40 - 3.36) 2001 Modelled IHME
2.93 (2.42 - 3.41) 2000 Modelled IHME
2.97 (2.47 - 3.45) 1999 Modelled IHME
3.01 (2.52 - 3.49) 1998 Modelled IHME
3.05 (2.55 - 3.51) 1997 Modelled IHME
3.08 (2.57 - 3.55) 1996 Modelled IHME
3.09 (2.58 - 3.58) 1995 Modelled IHME
3.08 (2.57 - 3.56) 1994 Modelled IHME
3.08 (2.57 - 3.56) 1993 Modelled IHME
3.06 (2.55 - 3.54) 1992 Modelled IHME
3.04 (2.49 - 3.54) 1991 Modelled IHME
3.01 (2.46 - 3.52) 1990 Modelled IHME
2.12 (0.36 - 13.86) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.16 (0.11 - 0.21) 2019 Modelled IHME
0.17 (0.12 - 0.22) 2018 Modelled IHME
0.17 (0.13 - 0.23) 2017 Modelled IHME
0.17 (0.13 - 0.22) 2016 Modelled IHME
0.17 (0.12 - 0.23) 2015 Modelled IHME
0.18 (0.13 - 0.24) 2014 Modelled IHME
0.19 (0.14 - 0.25) 2013 Modelled IHME
0.2 (0.15 - 0.27) 2012 Modelled IHME
0.21 (0.15 - 0.28) 2011 Modelled IHME
0.22 (0.16 - 0.29) 2010 Modelled IHME
0.22 (0.16 - 0.29) 2009 Modelled IHME
0.21 (0.16 - 0.28) 2008 Modelled IHME
0.21 (0.15 - 0.27) 2007 Modelled IHME
0.21 (0.15 - 0.27) 2006 Modelled IHME
0.21 (0.15 - 0.27) 2005 Modelled IHME
0.27 (0.20 - 0.35) 2004 Modelled IHME
0.44 (0.32 - 0.58) 2003 Modelled IHME
0.67 (0.49 - 0.88) 2002 Modelled IHME
0.91 (0.66 - 1.20) 2001 Modelled IHME
1.12 (0.81 - 1.50) 2000 Modelled IHME
1.33 (0.98 - 1.74) 1999 Modelled IHME
1.56 (1.16 - 2.01) 1998 Modelled IHME
1.77 (1.32 - 2.28) 1997 Modelled IHME
1.93 (1.43 - 2.49) 1996 Modelled IHME
2 (1.46 - 2.59) 1995 Modelled IHME
1.99 (1.46 - 2.56) 1994 Modelled IHME
1.99 (1.47 - 2.57) 1993 Modelled IHME
1.97 (1.45 - 2.54) 1992 Modelled IHME
1.94 (1.42 - 2.51) 1991 Modelled IHME
1.88 (1.37 - 2.47) 1990 Modelled IHME
0.25 (0.04 - 2.05) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
20 (14 - 27) 2019 Modelled IHME
20 (14 - 27) 2018 Modelled IHME
20 (14 - 27) 2017 Modelled IHME
20 (14 - 27) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
20 (14 - 27) 2014 Modelled IHME
20 (14 - 27) 2013 Modelled IHME
20 (15 - 28) 2012 Modelled IHME
21 (15 - 28) 2011 Modelled IHME
21 (15 - 29) 2010 Modelled IHME
21 (15 - 29) 2009 Modelled IHME
21 (15 - 29) 2008 Modelled IHME
21 (15 - 29) 2007 Modelled IHME
21 (15 - 30) 2006 Modelled IHME
22 (15 - 30) 2005 Modelled IHME
22 (15 - 30) 2004 Modelled IHME
22 (15 - 30) 2003 Modelled IHME
22 (16 - 31) 2002 Modelled IHME
22 (16 - 31) 2001 Modelled IHME
22 (16 - 31) 2000 Modelled IHME
22 (16 - 31) 1999 Modelled IHME
23 (16 - 31) 1998 Modelled IHME
23 (16 - 32) 1997 Modelled IHME
23 (17 - 31) 1996 Modelled IHME
23 (17 - 31) 1995 Modelled IHME
23 (17 - 31) 1994 Modelled IHME
23 (17 - 31) 1993 Modelled IHME
23 (17 - 31) 1992 Modelled IHME
23 (17 - 31) 1991 Modelled IHME
23 (17 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
97 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
95 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
94 2010 Survey/reported WHO/UNICEF
92 2009 Survey/reported WHO/UNICEF
91 2008 Survey/reported WHO/UNICEF
92 2007 Survey/reported WHO/UNICEF
92 2006 Survey/reported WHO/UNICEF
93 2005 Survey/reported WHO/UNICEF
94 2004 Survey/reported WHO/UNICEF
95 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
96 2001 Survey/reported WHO/UNICEF
97 2000 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
92 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
94 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
93 2014 Survey/reported WHO/UNICEF
95 2013 Survey/reported WHO/UNICEF
95 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
94 2010 Survey/reported WHO/UNICEF
93 2009 Survey/reported WHO/UNICEF
89 2008 Survey/reported WHO/UNICEF
85 2007 Survey/reported WHO/UNICEF
78 2006 Survey/reported WHO/UNICEF
91 2005 Survey/reported WHO/UNICEF
91 2004 Survey/reported WHO/UNICEF
93 2003 Survey/reported WHO/UNICEF
91 2002 Survey/reported WHO/UNICEF
69 2001 Survey/reported WHO/UNICEF
55 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
39 (18 - 58) 2015 Survey/reported Lazarus JV et al , 2015
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1999
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.48 (2.82 - 4.22) 2019 Modelled IHME
3.49 (2.82 - 4.25) 2018 Modelled IHME
3.49 (2.80 - 4.29) 2017 Modelled IHME
3.48 (2.86 - 4.20) 2016 Modelled IHME
3.47 (2.85 - 4.23) 2015 Modelled IHME
3.47 (2.86 - 4.21) 2014 Modelled IHME
3.47 (2.85 - 4.19) 2013 Modelled IHME
3.46 (2.84 - 4.19) 2012 Modelled IHME
3.46 (2.81 - 4.21) 2011 Modelled IHME
3.45 (2.78 - 4.25) 2010 Modelled IHME
3.44 (2.77 - 4.20) 2009 Modelled IHME
3.42 (2.74 - 4.19) 2008 Modelled IHME
3.4 (2.72 - 4.15) 2007 Modelled IHME
3.37 (2.71 - 4.17) 2006 Modelled IHME
3.34 (2.67 - 4.15) 2005 Modelled IHME
3.3 (2.64 - 4.09) 2004 Modelled IHME
3.25 (2.60 - 4.02) 2003 Modelled IHME
3.2 (2.58 - 3.95) 2002 Modelled IHME
3.14 (2.54 - 3.88) 2001 Modelled IHME
3.1 (2.49 - 3.85) 2000 Modelled IHME
3.05 (2.47 - 3.79) 1999 Modelled IHME
3.01 (2.42 - 3.70) 1998 Modelled IHME
2.96 (2.40 - 3.65) 1997 Modelled IHME
2.93 (2.37 - 3.59) 1996 Modelled IHME
2.92 (2.36 - 3.58) 1995 Modelled IHME
2.92 (2.36 - 3.58) 1994 Modelled IHME
2.92 (2.36 - 3.59) 1993 Modelled IHME
2.93 (2.36 - 3.61) 1992 Modelled IHME
2.95 (2.38 - 3.64) 1991 Modelled IHME
2.98 (2.38 - 3.69) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
42.7 (29.30 - 56.10) 2012 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
39 (30 - 49) 2019 Modelled IHME
40 (30 - 49) 2018 Modelled IHME
40 (30 - 49) 2017 Modelled IHME
40 (30 - 50) 2016 Modelled IHME
40 (30 - 49) 2015 Modelled IHME
40 (30 - 50) 2014 Modelled IHME
40 (30 - 50) 2013 Modelled IHME
40 (30 - 50) 2012 Modelled IHME
40 (30 - 49) 2011 Modelled IHME
40 (30 - 49) 2010 Modelled IHME
40 (30 - 50) 2009 Modelled IHME
40 (30 - 50) 2008 Modelled IHME
40 (30 - 49) 2007 Modelled IHME
40 (30 - 50) 2006 Modelled IHME
40 (29 - 49) 2005 Modelled IHME
39 (29 - 49) 2004 Modelled IHME
39 (29 - 49) 2003 Modelled IHME
39 (29 - 49) 2002 Modelled IHME
39 (29 - 48) 2001 Modelled IHME
38 (29 - 48) 2000 Modelled IHME
38 (28 - 48) 1999 Modelled IHME
38 (28 - 47) 1998 Modelled IHME
37 (28 - 47) 1997 Modelled IHME
37 (28 - 46) 1996 Modelled IHME
37 (28 - 46) 1995 Modelled IHME
37 (27 - 45) 1994 Modelled IHME
37 (27 - 45) 1993 Modelled IHME
37 (27 - 45) 1992 Modelled IHME
36 (27 - 45) 1991 Modelled IHME
36 (27 - 45) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (18 - 58) 2015 Survey/reported Lazarus JV et al , 2015
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
1999
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.09 (%)
2019
(1.72 - 2.37(%))
IHME
HCV (RNA/cAg+)
3.48 (%)
2019
(2.82 - 4.22(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
232
2019
(173 - 306)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
327
2019
(247 - 417)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.16 (%)
2019, latest modelled
(0.11 - 0.21(%))
IHME

Prevalence PWID

HCV
42.70 (%)
2012, latest modelled
(29.30 - 56.10(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
97 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
39
2015
(18 - 58)
Lazarus JV et al , 2015
Eligible for HBV generic medicines
Eligible for HCV generic medicines